HUTCHMED Starts Phase Ia Study of HMPL-A830 in Advanced Solid Tumors
HUTCHMED has begun a global Phase Ia trial of HMPL-A830, a KRAS inhibitor combined with an EGFR-targeting antibody, in patients with advanced solid tumors. The first patient was dosed in China on September 24, 2026, and the study will assess safety, tolerability, and dose selection. The program is linked to a September 3, 2026 agreement granting GSK development and commercialization rights outside Greater China, with HUTCHMED responsible for the global Phase I program.
Expanded:
HUTCHMED has begun first-in-human testing of HMPL-A830. This multicenter Phase Ia is recruiting people whose solid tumors cannot be surgically removed or have advanced/metastasized. The first dose was given in China on September 24, 2026. The therapy pairs a KRAS-blocking agent with an antibody aimed at EGFR. Early aims cover safety, tolerability, how the drug moves through the body, immune response, highest tolerable dose, and a dose for expansion.
A later expansion/optimization stage will examine safety and initial anti-tumor activity in selected tumor types. Under the September 3, 2026 exclusive arrangement, a GSK subsidiary would obtain development and commercialization rights outside Mainland China, Hong Kong, Macau, and Taiwan, with $110 million upfront, pending closing conditions such as antitrust review. HUTCHMED's subsidiary handles the global Phase I program.
Count P1: HUTCHMED1 has2 begun3 first-in-human4 testing5 of6 HMPL-A830.7 This8 multicenter9 Phase10 Ia11 is12 recruiting13 people14 whose15 solid16 tumors17 cannot18 be19 surgically20 removed21 or22 have23 advanced/metastasized.24 The25 first26 dose27 was28 given29 in30 China31 on32 September33 24,34 2026.35 The36 therapy37 pairs38 a39 KRAS-blocking40 agent41 with42 an43 antibody44 aimed45 at46 EGFR.47 Early48 aims49 cover50 safety,51 tolerability,52 how53 the54 drug55 moves56 through57 the58 body,59 immune60 response,61 highest62 tolerable63 dose,64 and65 a66 dose67 for68 expansion.69
P2: A1 later2